Ariana Pelosci

Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.

Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.

In April, the FDA approved decabtagene vicleucel (ide-cel) for earlier treatment of relapsed/refractory multiple myleoma.

The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.

Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation.

Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.